—ETR
— • —
$116.47
P/E
29.52
PEG
—
FCF Yield
—
Rev Growth YoY
+917.0% YoY
Gross Margin
4204.5%
Health Score
4/10
D/E Ratio
1.80
Confidence
LOW
Business Snapshot
The ticker and exchange data provided in this payload are incomplete, which limits identification of the specific company. Based on available data, the stock is trading at $116.47 with a P/E ratio of 29.52x and a Price/Sales ratio of 4.13x, suggesting a profitable, revenue-generating business. Without a confirmed market capitalisation figure, the cap tier cannot be determined with certainty, which itself is a transparency concern.
Financial Health
**Score: 4/10** The reported gross margin of 4,204.5% and net margin of 1,376.0% are statistically implausible and almost certainly reflect a data anomaly — such as a near-zero cost base in the comparison period or a one-time accounting adjustment — rather than genuine operational efficiency. The balance sheet shows a debt/equity ratio of 1.8x, which is moderate but not alarming in isolation...
Risk Assessment
- **DATA INTEGRITY:** Gross margin of 4,204.5% and net margin of 1,376.0% are economically implausible and strongly suggest data corruption, restatement effects, or an extreme base-period distortion. - **EARNINGS DETERIORATION:** Earnings growth of -714.0% YoY directly contradicts the revenue growth story, signalling that costs or losses are expanding far faster than revenue. - **LIQUIDITY:** Current ratio of 0.74x falls below 1.0x, meaning short-term liabilities exceed short-term assets, creating potential near-term refinancing or operational pressure. - **VALUATION OPACITY:** FCF, EV/EBITDA, DCF fair value, and PEG ratio are all unavailable, removing four of the most critical tools for assessing whether $116.47 is a fair price. - **TECHNICAL WEAKNESS:** A confirmed death cross (50-day MA crossing below 200-day MA) combined with a bearish MACD signal indicates the price trend is deteriorating on a medium-to-long-term basis. ---...